Erudio Healtherudio.com
Clinical trial · no report yet · Phase 3
EXCLAIM-2
TAK-788 as First-Line Treatment Versus Platinum-Based Chemotherapy for Non-Small Cell Lung Cancer (NSCLC) With EGFR Exon 20 Insertion Mutations
- NCT04129502 ↗
- Completed
- Takeda
- Deep
We haven't built an HCP commentary report on EXCLAIM-2 (TAK-788, pemetrexed and 2 more in Advanced/Metastatic Non-Small Cell Lung Cancer (NSCLC)) yet. This page shows the registry record and the public commentary we found that names the trial. A report reads that commentary and sets out what clinicians said about the trial, each point linked to its source. How reports are made.
Indexed commentary on EXCLAIM-2 so far
Podcasts, YouTube videos and X posts we have indexed that name the trial. It is where a report starts, not where it ends: the build searches for more, so finished reports usually cover more than this.
| Channel | Indexed | |
|---|---|---|
| X threads | 22 | |
| YouTube | 6 | |
| Podcasts | 6 |
The trial
ClinicalTrials.gov- Official title
- A Randomized Phase 3 Multicenter Open-Label Study to Compare the Efficacy of TAK-788 as First-Line Treatment Versus Platinum-Based Chemotherapy in Patients With Non-Small Cell Lung Cancer With EGFR Exon 20 Insertion Mutations
- Phase
- Phase 3
- Status
- Completed
- Conditions
- Advanced/Metastatic Non-Small Cell Lung Cancer (NSCLC)
- Interventions
- TAK-788; Pemetrexed; Cisplatin; Carboplatin
- Arms
- TAK-788 Group (Arm A) · Experimental
- Platinum-based Chemotherapy Group (Arm B) · Active comparator
- Enrollment
- 354
- Primary outcomes
- Progression Free Survival (PFS) as Assessed by Blinded Independent Review Committee (IRC) per Response Evaluation Criteria in Solid Tumors (RECIST) Version 1.1
- Sponsor
- Takeda
- Start
- Jan 10, 2020
- Primary completion
- Sep 22, 2026
- Results posted
- No
- Registry record
- NCT04129502 · updated Oct 23, 2026
Publications
linked from the registry- Janne PA, Wang BC, Cho BC, Zhao J, Li J, Hochmair M, Peters S, Besse B, Pavlakis N, Neal JW, Kato T, Wu YL, Nguyen D, Lin J, Lin J, Vranceanu F, Szumski A, Lin HM, Fram RJ, Mok TSK. First-Line Mobocertinib Versus Platinum-Based Chemotherapy in Patients With EGFR Exon 20 Insertion-Positive Metastatic Non-Small Cell Lung Cancer in the Phase III EXCLAIM-2 Trial. J Clin Oncol. 2025 May;43(13):1553-1563. doi: 10.1200/JCO-24-01269. Epub 2025 Jan 29. PubMed 39879577